I

Instituto Nacional de Pediatria | Clinical Research Support Unit | Mexico City, United States

Research site

(Unclaimed)

Location

Insurgentes Sur 3700-C, Mexico City, Ciudad de Mexico, Mexico

Site insights

Top conditions

Top treatments

Meropenem

MK-7625A

Vericiguat

MK-5592

MK-5592-104

Tedizolid Phosphate

Iron

Bezlotoxumab

MK-1242-036

Pazufloxacin

Parent organization

This site is a part of Instituto Nacional de Pediatria

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 25 total trials

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Primary Objectives:To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemi...

Enrolling

Chronic Kidney Disease; Iron Deficiency Anemia

Drug: Iron sucrose

Drug: Ferumoxytol

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 wee...

Enrolling

Human Immunodeficiency Virus (HIV) Infection

Drug: 2 NRTIs

Drug: Doravirine

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline t...

Enrolling

Left Ventricular Systolic Dysfunction

Heart Failure

Drug: Placebo tablet

Drug: Placebo suspension

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and e...

Enrolling

COVID-19

Drug: nirmatrelvir

Drug: ritonavir